London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating ...
Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aims to harness, direct and optimize their immune suppressive properties to address serious ...
The advancement of QEL-005 into clinical testing comes shortly after London-headquartered Quell said it was calling a ...
Quell Therapeutics has begun its chill phase 1/2 clinical trial evaluating QEL‑005, an autologous CAR‑Treg therapy designed ...
Add Yahoo as a preferred source to see more of our stories on Google. Treg cells have been thrust into the limelight thanks to the Nobel Prize-winning work of a team of researchers from the U.S. and ...
Regeneron Pharmaceuticals already has a presence in immunology, but nothing in its portfolio or pipeline addresses inflammatory bowel disorders nor does the drugmaker have any cell therapies. The ...
Lung cancer cells are able to take advantage of a person’s immune system, specifically T cells, to protect the tumor, ...
Understanding how regulatory T cells (Tregs) develop and work is key to determining how they might be manipulated to encourage the destruction of cancer cells or prevent autoimmunity. Cell behavior is ...
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by polyclonal activation of B and T lymphocytes. In addition to Th1 and Th2 cells imbalance, the roles of regulatory T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results